Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science

被引:10
作者
Finlay, Andrea K. [1 ,2 ]
Binswanger, Ingrid A. [3 ,4 ]
Timko, Christine [1 ,5 ]
Smelson, David [6 ]
Stimmel, Matthew A. [7 ]
Yu, Mengfei [1 ]
Bowe, Tom [1 ]
Harris, Alex H. S. [1 ,8 ]
机构
[1] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA
[2] US Dept Vet Affairs, Natl Ctr Homelessness Vet, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA
[3] Kaiser Permanente Colorado, Inst Hlth Res, POB 378066, Denver, CO 80237 USA
[4] Univ Colorado, Sch Med, Div Gen Internal Med, 12631 E 17th Ave,Acad Off One,Campus Box B180, Aurora, CO 80045 USA
[5] Stanford Univ, Dept Psychiat & Behav Med, Sch Med, 401 Quarry Rd, Stanford, CA 94305 USA
[6] Edith Nourse Rogers VA Med Ctr, Ctr Org & Implementat Sci, 200 Springs, Bedford, MA 01730 USA
[7] VA Palo Alto Hlth Care Syst, Vet Justice Outreach Program, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA
[8] Stanford Univ, Sch Med, Dept Surg, Alway Bldg Room M121,300 Pasteur Dr, Stanford, CA 94305 USA
基金
美国国家卫生研究院;
关键词
Opioid-related disorders; Pharmacotherapy; Methadone; Buprenorphine; United States Department of Veterans Affairs; Implementation science; HEALTH ADMINISTRATION PATIENTS; MEDICATION-ASSISTED TREATMENT; ADDICTION TREATMENT; QUALITY MEASURES; BARRIERS; BUPRENORPHINE; SERVICES; TRENDS;
D O I
10.1016/j.jsat.2018.09.006
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: The U.S. is facing an opioid epidemic, but despite mandates for pharmacotherapy for opioid use disorder to be available at Veterans Health Administration (VHA) facilities, the majority of veterans with opioid use disorder do not receive these medications. In implementation research, facilities are often targeted for qualitative inquiry or quality improvement efforts based on quality measure performance during a one-year period. However, sites that experience quality performance changes from one year to the next. may be highly informative because mechanisms that impact facility change may be more discoverable. The current study examined changes in receipt of pharmacotherapy for opioid use disorder in a national healthcare system to determine the extent to which sites fluctuated in performance over a two-year period and illustrate how changes in quality measures over time may be useful for implementation research and healthcare surveillance of quality measures. Methods: Using national VHA data from Fiscal Years (FY) 2016 and 2017, we calculated quality measure performance as the number of patients who received pharmacotherapy for opioid use disorder (i.e., methadone, buprenorphine, and naltrexone) divided by the number of patients with a current non-remitted opioid use disorder diagnosis for each FY at each facility (n = 129) and examined change from FY16 to FY17. Results: The mean rate of receipt of pharmacotherapy for opioid use disorder was 38% (facility range = 3% to 74%) in FY16 and 41% (facility range = 2% to 76%) in FY17. The average facility-level change in performance was 3% and ranged from 19% to 26%. There were 32 facilities that decreased in provision of pharmacotherapy, 12 facilities with no change, and 85 facilities that increased. Conclusions: For facilities with average or high performance, it was difficult to maintain their performance over time. Identifying and learning from facilities with recent fluctuations may be more informative to guide the design of future quality improvement efforts than studying facilities with stable high or low performance.
引用
收藏
页码:43 / 47
页数:5
相关论文
共 28 条
[1]   Counselor training and attitudes toward pharmacotherapies for opioid use disorder [J].
Aletraris, Lydia ;
Edmond, Mary Bond ;
Paino, Maria ;
Fields, Dail ;
Roman, Paul M. .
SUBSTANCE ABUSE, 2016, 37 (01) :47-53
[2]   An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research [J].
Amato, L ;
Davoli, M ;
Perucci, CA ;
Ferri, M ;
Faggiano, F ;
Mattick, RP .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2005, 28 (04) :321-329
[3]   Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence [J].
Amato, Laura ;
Minozzi, Silvia ;
Davoli, Marina ;
Vecchi, Simona .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (10)
[4]  
[Anonymous], IMPL SCI INF RES
[5]   Integrating Buprenorphine Treatment into Office-based Practice: a Qualitative Study [J].
Barry, Declan T. ;
Irwin, Kevin S. ;
Jones, Emlyn S. ;
Becker, William C. ;
Tetrault, Jeanette M. ;
Sullivan, Lynn E. ;
Hansen, Helena ;
O'Connor, Patrick G. ;
Schottenfeld, Richard S. ;
Fiellin, David A. .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 (02) :218-225
[6]   Trends and Regional Variation in Opioid Overdose Mortality Among Veterans Health Administration Patients, Fiscal Year 2001 to 2009 [J].
Bohnert, Amy S. B. ;
Ilgen, Mark A. ;
Trafton, Jodie A. ;
Kerns, Robert D. ;
Eisenberg, Anna ;
Ganoczy, Dara ;
Blow, Frederic C. .
CLINICAL JOURNAL OF PAIN, 2014, 30 (07) :605-612
[7]   When Quality Indicators Undermine Quality: Bias in a Quality Indicator of Follow-Up for Alcohol Misuse [J].
Bradley, Katharine A. ;
Chavez, Laura J. ;
Lapham, Gwendolyn T. ;
Williams, Emily C. ;
Achtmeyer, Carol E. ;
Rubinsky, Anna D. ;
Hawkins, Eric J. ;
Saitz, Richard ;
Kivlahan, Daniel R. .
PSYCHIATRIC SERVICES, 2013, 64 (10) :1018-1025
[8]   Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians [J].
Cunningham, Chinazo O. ;
Kunins, Hillary V. ;
Roose, Robert J. ;
Elam, Rashiah T. ;
Sohler, Nancy L. .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2007, 22 (09) :1325-1329
[9]  
Department of Veterans Affairs, 2008, VHA HDB
[10]  
Department of Veterans Affairs Department of Defense, 2015, VA DOD CLIN PRACT GU VA DOD CLIN PRACT GU